PET of Hypoxia with 89Zr-Labeled cG250-F(ab′)2 in Head and Neck Tumors

Hypoxic tumor cells are resistant to radiotherapy and various chemotherapeutic agents. The pretherapeutic assessment of intratumoral hypoxia may allow selection of patients for intensified treatment regimens. Carbonic anhydrase IX (CAIX) is an endogenous hypoxia-related protein involved in pH regulation and is upregulated in many tumor types. Radionuclide imaging using a monoclonal antibody against CAIX, such as cG250, may allow noninvasive PET of hypoxia in these tumor types. The aims of this study were to investigate whether 89Zr-labeled cG250-F(ab′)2 allowed visualization of tumor hypoxia using small-animal PET and whether the tracer showed spatial correlation to the microscopic distribution of CAIX-expressing cells in a human head and neck xenograft tumor model. Methods: Athymic mice with subcutaneous human head and neck carcinoma xenografts (SCCNij3) were imaged with small-animal PET after injection of 89Zr-cG250-F(ab′)2. PET images were parameterized in terms of standardized uptake values (SUVs). After injection with the nitroimidazole hypoxia marker pimonidazole and the perfusion marker Hoechst 33342, the animals were sacrificed, tumors excised, and CAIX- and pimonidazole-marked hypoxia and blood perfusion were analyzed immunohistochemically. 89Zr-cG250-F(ab′)2 tumor uptake was analyzed by ex vivo activity counting and by autoradiography of tumor sections. Results: As early as 4 h after administration, accumulation of 89Zr-cG250-F(ab′)2 in the tumor had occurred and tumors were clearly visualized by PET, with reduced uptake by 24 h after injection. Pixel-by-pixel analysis showed a significant positive spatial correlation between CAIX expression and 89Zr-cG250-F(ab′)2 localization (r = 0.57–0.74; P < 0.0001). Also, significant correlations were found between pimonidazole staining intensity and 89Zr-cG250-F(ab′)2 activity concentration, although less strong (r = 0.46–0.68; P < 0.0001). Tumor maximum SUV correlated significantly with tumor uptake determined ex vivo (r = 0.93; P = 0.0067), as did fractions of CAIX and pimonidazole in tumor sections (r = 0.75; P = 0.03 and r = 0.78; P = 0.02, respectively). Conclusion: 89Zr-labeled cG250-F(ab′)2 small-animal PET showed rapid accumulation in a head and neck xenograft tumor model with good correlation to CAIX expression on a microscopic level.

[1]  A. Scott,et al.  Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT. , 2011, Urologic oncology.

[2]  J. Kaanders,et al.  Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia. , 2009, European journal of cancer.

[3]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[4]  G. V. van Dongen,et al.  p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  U. Qureshi,et al.  Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours , 2009, British Journal of Cancer.

[6]  Martin Gotthardt,et al.  Spatial Resolution and Sensitivity of the Inveon Small-Animal PET Scanner , 2008, Journal of Nuclear Medicine.

[7]  J. Bussink,et al.  Molecular aspects of tumour hypoxia , 2008, Molecular oncology.

[8]  J. Bussink,et al.  Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. , 2008, International journal of radiation oncology, biology, physics.

[9]  J. Humm,et al.  Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. , 2007, The Lancet. Oncology.

[10]  W. Oyen,et al.  Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  Y. Yonekura,et al.  Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. , 2006, Nuclear medicine and biology.

[12]  P. D. de Wilde,et al.  The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  J. Bowsher,et al.  Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  A. Harris,et al.  Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Bussink,et al.  Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  J. Bussink,et al.  Hypoxic cell turnover in different solid tumor lines. , 2005, International journal of radiation oncology, biology, physics.

[17]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. , 2005, Journal of medicinal chemistry.

[18]  C Clifton Ling,et al.  Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor mo , 2005, International journal of radiation oncology, biology, physics.

[19]  Søren M Bentzen,et al.  Theragnostic imaging for radiation oncology: dose-painting by numbers. , 2005, The Lancet. Oncology.

[20]  W. Oyen,et al.  Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. , 2004, Cancer biotherapy & radiopharmaceuticals.

[21]  Johan Bussink,et al.  Clinical studies of hypoxia modification in radiotherapy. , 2004, Seminars in radiation oncology.

[22]  R. Boellaard,et al.  89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  C. Sweep,et al.  Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome , 2003, British Journal of Cancer.

[24]  A. Harris,et al.  GLUT‐1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding , 2003, International journal of cancer.

[25]  Johan Bussink,et al.  Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. , 2002, Cancer research.

[26]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[27]  P H Watson,et al.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.

[28]  J. Bussink,et al.  Optical Sensor-Based Oxygen Tension Measurements Correspond with Hypoxia Marker Binding in Three Human Tumor Xenograft Lines , 2000, Radiation research.

[29]  R J Hodgkiss,et al.  Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. , 2000, International journal of radiation oncology, biology, physics.

[30]  R. Brakenhoff,et al.  Molecular cloning and immunogenicity of renal cell carcinoma‐associated antigen G250 , 2000, International journal of cancer.

[31]  E. T. Gawlinski,et al.  A reaction-diffusion model of cancer invasion. , 1996, Cancer research.

[32]  R. Kettmann,et al.  Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. , 1996, Genomics.

[33]  P. Kenemans,et al.  Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic mice. , 1991, Anticancer research.

[34]  G. Fleuren,et al.  Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal‐cell carcinoma xenografts: Relative effects of size and affinity , 1991, International journal of cancer.

[35]  D. Ruiter,et al.  Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidney , 1986, International journal of cancer.

[36]  J N Weinstein,et al.  Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. , 1986, Cancer research.

[37]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[38]  S. Pastoreková,et al.  Tumor-associated carbonic anhydrases and their clinical significance. , 2006, Advances in clinical chemistry.

[39]  L. Khawli,et al.  Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. , 2003, Cancer biotherapy & radiopharmaceuticals.

[40]  Michael Unser,et al.  A pyramid approach to subpixel registration based on intensity , 1998, IEEE Trans. Image Process..